Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation

Adriana Valentini, Amy Finch, Jan Lubinśki, Tomasz Byrski, Parviz Ghadirian, Charmaine Kim-Sing, Henry T. Lynch, Peter J. Ainsworth, Susan L. Neuhausen, Ellen Greenblatt, Christian Singer, Ping Sun, Steven A. Narod

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: To determine the likelihood of long-term amenorrhea after treatment with chemotherapy in women with breast cancer who carry a BRCA1 or BRCA2 mutation. Patients and Methods: We conducted a multicenter survey of 1,954 young women with a BRCA1 or BRCA2 mutation who were treated for breast cancer. We included premenopausal women who were diagnosed with invasive breast cancer between 26 and 47 years of age. We determined the age of onset of amenorrhea after breast cancer for women who were and were not treated with chemotherapy, alone or with tamoxifen. We considered chemotherapy-induced amenorrhea to have occurred when the patient experienced ≥ 2 years of amenorrhea, commencing within 2 years of initiating chemotherapy, with no resumption of menses. Results: Of the 1,426 women who received chemotherapy, 35% experienced long-term amenorrhea. Of the 528 women who did not receive chemotherapy, 5.3% developed long-term amenorrhea. The probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed before age 30 years, 33% for women age 31 to 44 years, and 79% for women diagnosed after age 45 years (P trend <.001). The probability of induced amenorrhea was higher for women who received tamoxifen than for those who did not (52% v 29%; P <.001). Conclusion: Age at treatment and use of tamoxifen are important predictors of chemotherapy-induced amenorrhea in women who carry a BRCA1 or BRCA2 mutation. The risk of induced long-term amenorrhea does not seem to be greater among mutation carriers than among women who do not carry a mutation.

Original languageEnglish
Pages (from-to)3914-3919
Number of pages6
JournalJournal of Clinical Oncology
Volume31
Issue number31
DOIs
StatePublished - Nov 1 2013

Fingerprint

Amenorrhea
Breast Neoplasms
Drug Therapy
Mutation
Tamoxifen
Menstruation
Age of Onset

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Valentini, A., Finch, A., Lubinśki, J., Byrski, T., Ghadirian, P., Kim-Sing, C., ... Narod, S. A. (2013). Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 31(31), 3914-3919. https://doi.org/10.1200/JCO.2012.47.7893

Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. / Valentini, Adriana; Finch, Amy; Lubinśki, Jan; Byrski, Tomasz; Ghadirian, Parviz; Kim-Sing, Charmaine; Lynch, Henry T.; Ainsworth, Peter J.; Neuhausen, Susan L.; Greenblatt, Ellen; Singer, Christian; Sun, Ping; Narod, Steven A.

In: Journal of Clinical Oncology, Vol. 31, No. 31, 01.11.2013, p. 3914-3919.

Research output: Contribution to journalArticle

Valentini, A, Finch, A, Lubinśki, J, Byrski, T, Ghadirian, P, Kim-Sing, C, Lynch, HT, Ainsworth, PJ, Neuhausen, SL, Greenblatt, E, Singer, C, Sun, P & Narod, SA 2013, 'Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation', Journal of Clinical Oncology, vol. 31, no. 31, pp. 3914-3919. https://doi.org/10.1200/JCO.2012.47.7893
Valentini A, Finch A, Lubinśki J, Byrski T, Ghadirian P, Kim-Sing C et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology. 2013 Nov 1;31(31):3914-3919. https://doi.org/10.1200/JCO.2012.47.7893
Valentini, Adriana ; Finch, Amy ; Lubinśki, Jan ; Byrski, Tomasz ; Ghadirian, Parviz ; Kim-Sing, Charmaine ; Lynch, Henry T. ; Ainsworth, Peter J. ; Neuhausen, Susan L. ; Greenblatt, Ellen ; Singer, Christian ; Sun, Ping ; Narod, Steven A. / Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 31. pp. 3914-3919.
@article{e647d5c5d93b4902ac0d5aeceb1cadd2,
title = "Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation",
abstract = "Purpose: To determine the likelihood of long-term amenorrhea after treatment with chemotherapy in women with breast cancer who carry a BRCA1 or BRCA2 mutation. Patients and Methods: We conducted a multicenter survey of 1,954 young women with a BRCA1 or BRCA2 mutation who were treated for breast cancer. We included premenopausal women who were diagnosed with invasive breast cancer between 26 and 47 years of age. We determined the age of onset of amenorrhea after breast cancer for women who were and were not treated with chemotherapy, alone or with tamoxifen. We considered chemotherapy-induced amenorrhea to have occurred when the patient experienced ≥ 2 years of amenorrhea, commencing within 2 years of initiating chemotherapy, with no resumption of menses. Results: Of the 1,426 women who received chemotherapy, 35{\%} experienced long-term amenorrhea. Of the 528 women who did not receive chemotherapy, 5.3{\%} developed long-term amenorrhea. The probabilities of chemotherapy-induced amenorrhea were 7.2{\%} for women diagnosed before age 30 years, 33{\%} for women age 31 to 44 years, and 79{\%} for women diagnosed after age 45 years (P trend <.001). The probability of induced amenorrhea was higher for women who received tamoxifen than for those who did not (52{\%} v 29{\%}; P <.001). Conclusion: Age at treatment and use of tamoxifen are important predictors of chemotherapy-induced amenorrhea in women who carry a BRCA1 or BRCA2 mutation. The risk of induced long-term amenorrhea does not seem to be greater among mutation carriers than among women who do not carry a mutation.",
author = "Adriana Valentini and Amy Finch and Jan Lubinśki and Tomasz Byrski and Parviz Ghadirian and Charmaine Kim-Sing and Lynch, {Henry T.} and Ainsworth, {Peter J.} and Neuhausen, {Susan L.} and Ellen Greenblatt and Christian Singer and Ping Sun and Narod, {Steven A.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1200/JCO.2012.47.7893",
language = "English",
volume = "31",
pages = "3914--3919",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation

AU - Valentini, Adriana

AU - Finch, Amy

AU - Lubinśki, Jan

AU - Byrski, Tomasz

AU - Ghadirian, Parviz

AU - Kim-Sing, Charmaine

AU - Lynch, Henry T.

AU - Ainsworth, Peter J.

AU - Neuhausen, Susan L.

AU - Greenblatt, Ellen

AU - Singer, Christian

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Purpose: To determine the likelihood of long-term amenorrhea after treatment with chemotherapy in women with breast cancer who carry a BRCA1 or BRCA2 mutation. Patients and Methods: We conducted a multicenter survey of 1,954 young women with a BRCA1 or BRCA2 mutation who were treated for breast cancer. We included premenopausal women who were diagnosed with invasive breast cancer between 26 and 47 years of age. We determined the age of onset of amenorrhea after breast cancer for women who were and were not treated with chemotherapy, alone or with tamoxifen. We considered chemotherapy-induced amenorrhea to have occurred when the patient experienced ≥ 2 years of amenorrhea, commencing within 2 years of initiating chemotherapy, with no resumption of menses. Results: Of the 1,426 women who received chemotherapy, 35% experienced long-term amenorrhea. Of the 528 women who did not receive chemotherapy, 5.3% developed long-term amenorrhea. The probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed before age 30 years, 33% for women age 31 to 44 years, and 79% for women diagnosed after age 45 years (P trend <.001). The probability of induced amenorrhea was higher for women who received tamoxifen than for those who did not (52% v 29%; P <.001). Conclusion: Age at treatment and use of tamoxifen are important predictors of chemotherapy-induced amenorrhea in women who carry a BRCA1 or BRCA2 mutation. The risk of induced long-term amenorrhea does not seem to be greater among mutation carriers than among women who do not carry a mutation.

AB - Purpose: To determine the likelihood of long-term amenorrhea after treatment with chemotherapy in women with breast cancer who carry a BRCA1 or BRCA2 mutation. Patients and Methods: We conducted a multicenter survey of 1,954 young women with a BRCA1 or BRCA2 mutation who were treated for breast cancer. We included premenopausal women who were diagnosed with invasive breast cancer between 26 and 47 years of age. We determined the age of onset of amenorrhea after breast cancer for women who were and were not treated with chemotherapy, alone or with tamoxifen. We considered chemotherapy-induced amenorrhea to have occurred when the patient experienced ≥ 2 years of amenorrhea, commencing within 2 years of initiating chemotherapy, with no resumption of menses. Results: Of the 1,426 women who received chemotherapy, 35% experienced long-term amenorrhea. Of the 528 women who did not receive chemotherapy, 5.3% developed long-term amenorrhea. The probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed before age 30 years, 33% for women age 31 to 44 years, and 79% for women diagnosed after age 45 years (P trend <.001). The probability of induced amenorrhea was higher for women who received tamoxifen than for those who did not (52% v 29%; P <.001). Conclusion: Age at treatment and use of tamoxifen are important predictors of chemotherapy-induced amenorrhea in women who carry a BRCA1 or BRCA2 mutation. The risk of induced long-term amenorrhea does not seem to be greater among mutation carriers than among women who do not carry a mutation.

UR - http://www.scopus.com/inward/record.url?scp=84891637816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891637816&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.47.7893

DO - 10.1200/JCO.2012.47.7893

M3 - Article

VL - 31

SP - 3914

EP - 3919

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -